The subsidiary ProciseDx announces distribution agreement with Revvity’s EUROIMMUN US for the distribution of the ProciseDx platform in the United State and Canada

In this section

The subsidiary ProciseDx announces distribution agreement with Revvity’s EUROIMMUN US for the distribution of the ProciseDx platform in the United State and Canada

Apr 29, 2024 | News

Reading Time: 4 minutes


San Diego, April 29th, 2024

ProciseDx, a 100% subsidiary of Biosynex and an innovator in the development of reliable, rapid and easy-to-use delocalized biology systems, announces a strategic agreement with Revvity’s EUROIMMUN US INC., a leading provider of high quality in-vitro diagnostics products, for the exclusive distribution of the ProciseDx platform in the US and Canadian markets.

The ProciseDx platform was the first to receive de novo FDA approval in September 2023 for assays for infliximab (Remicade® and biosimilars Renflexis® and Inflectra®) and adalimumab (Humira® and biosimilar Amgevita®) used in Therapeutic Drug Monitoring (TDM).

These tests are used to quantify the serum concentration of infliximab (IFX) and adalimumab (ADL) in patients with inflammatory bowel disease (IBD) treated with these drugs. These tests are intended for use in hospitals and other clinical laboratories of moderate complexity. In the United States, 4.3 million people suffer from IBD (Crohn’s disease and ulcerative colitis), and up to 15% of them are treated with IFX and ADL.

Biological drugs such as Remicade® and Humira® are biotechnology-derived products for the treatment of chronic diseases. They represent the main cost factor in the treatment of IBD, according to a cost study carried out by the Crohn’s and Colitis Foundation. The cost of treatment in the United States for IBD patients taking biologics is between $20,000 and $60,000 a year. The measurement of these drugs can help doctors understand why certain patients respond or don’t respond to treatment, enabling more personalized treatment.

ProciseDx will leverage the strong commercial presence and scientific leadership of EUROIMMUN US in the distribution of in vitro diagnostic systems in the United States and Canada to target key market segments. In addition, ProciseDx will retain direct access to prospects with whom it has initiated referral discussions.

“We are delighted with this partnership with EUROIMMUN US which will enable us to extend our commercial coverage in North America and enable IBD patients to benefit from better management of their pathology thanks to immediate results. This agreement with EUROIMMUN US reinforces our strategic partnership in the field of TDM with EUROIMMUN initiated several years ago by Theradiag to market the iTracker range in numerous countries. It illustrates the strong synergies resulting from the acquisition of ProciseDx and the merger with Theradiag,” commented Larry Abensur, Chairman and CEO of BIOSYNEX.

Larry Abensur, Chairman and CEO of BIOSYNEX.

Next communication:
Turnover 2nd Quarter 2024 : July 18, 2024 post trading

In the press:


Founded in 2005, French laboratory BIOSYNEX is a leading healthcare diagnostics group, specializing in rapid tests, biotherapy monitoring and molecular biology.

As a key player in the medicine of the future, BIOSYNEX offers innovative healthcare solutions that improve overall patient care to a wide range of users, including laboratories, hospitals, physicians and the general public.

In the wake of the Covid-19 pandemic, to which BIOSYNEX made a major contribution, the Group has acquired a new international dimension in the field of rapid diagnostics, thanks in particular to a policy of dynamic external growth, with “Point of Care” products and technologies. BIOSYNEX PHARMACIE and BIOSYNEX DIAGNOSTICS have research, production and distribution subsidiaries in the United States, Europe and Asia,

For the general public: the BIOSYNEX Pharma division, which specializes in self-diagnostics and family health products, markets to a wide network of pharmacies and parapharmacies a complete range of strong, recognized brands in the fields of prevention, diagnostics and natural care.

For professionals: the BIOSYNEX Diagnostic division, a high-tech business positioned in growth sectors, develops and offers in vitro diagnostic medical devices in the form of rapid diagnostic tests (RDTs), molecular biology tests and point-of-care (POC) tests for screening, diagnosis and prevention to laboratories, hospitals, doctors and nursing homes.

Based in Illkirch-Graffenstaden, Alsace, the BIOSYNEX Group employs over 550 people and has a presence in 95 countries. The Group achieved sales of €93 million in 2023. Listed on Euronext Growth Paris (FR0011005933 ALBIO), BIOSYNEX is eligible for PEA PME.

For more information:

About EUROIMMUN and Revvity

As one of the leading manufacturers of medical laboratory diagnostics worldwide, EUROIMMUN stands for innovation. More than 3500 employees in 17 countries develop, produce and sell test systems to support the diagnosis of diseases, as well as software and automation solutions for the performance and evaluation of these tests. Laboratories in over 140 countries use EUROIMMUN products for the diagnosis of autoimmune and infectious diseases as well as allergies, and to perform genetic analyses.

The company was founded in 1987 from the University of Lübeck (Germany) and is part of Revvity, Inc., located in Waltham, Massachusetts. With revenues of more than $2.7 billion in 2023 and over 11,000 employees worldwide, Revvity serves customers in pharmaceutical and biotech companies, diagnostic labs, academia, and governments in more than 190 countries. It is included in the S&P 500 Index.

For more information, visit and




Privacy Policy | Sitemap